Leerink Partners Reiterates Outperform Rating on Celldex Therapeutics (CLDX)
Tweet Send to a Friend
Leerink Partners analyst Thomas Smith reiterated an Outperform rating and $78.00 price target on Celldex Therapeutics (NASDAQ: CLDX).The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
